Company Overview of Taisho Pharmaceutical Co., Ltd.
Taisho Pharmaceutical Co., Ltd. manufactures and sells over-the-counter (OTC) medicines and health-related products. The company offers its products in the areas of CNS, diabetes, immunology/allergy, and infectious diseases; and provides self-medication products, such as Rx-to-OTC switch drugs, eye drops, cold remedy medication products, gastrointestinal medication products, energy drinks, hair re-growth treatment medication products, and foods for specified health use. It also provides prescription pharmaceutical products, such as macrolide antibiotics, injectable antibiotics, peripheral vasodilators, nonsteroidal anti-inflammatory drugs, and infection and inflammation/immune-related produc...
Founded in 2011
Key Executives for Taisho Pharmaceutical Co., Ltd.
President and Representative Director
Executive Vice President and Director
Senior Executive Officer and Director
Corporate Adviser and Director
Compensation as of Fiscal Year 2015.
Taisho Pharmaceutical Co., Ltd. Key Developments
Polyphor and Taisho Pharmaceutical Enter into Research Collaboration on Novel Drug Candidates
Sep 17 15
Polyphor Ltd. announced the signing of a research collaboration agreement with Taisho Pharmaceutical Co., Ltd. The parties will collaborate on the identification of novel drug candidates based on Polyphor's proprietary macrocycle platform.
Taisho Pharmaceutical Co., Ltd. Announces Results from Phase III Osteoarthritis Trials
Jul 30 15
Taisho Pharmaceutical Co., Ltd. has announced results from two Phase III clinical trials with the anti-inflammatory analgesic patch formulation containing S-flurbiprofen, or TT-063, in patients with osteoarthritis. The clinical trials investigated the efficacy of applying TT-063 for two weeks, targeting 633 patients with osteoarthritis of the knee joint. The patients were divided into a group of patients to whom TT-063 was administered, and a group of patients to whom a flurbiprofen gel patch (FP) was administered as a control drug. The trials compared the two groups. The primary endpoint of the study was the change in the assessment of pain when standing. The change in this pain assessment before and after application of the patch was 40.9 mm for the TT-063 group and 30.6 mm for the FP group. As a result, the TT-063 group demonstrated significantly superior efficacy relative to the FP group. In other areas, the TT-063 group demonstrated clinically higher efficacy in terms of the assessment of pain when walking (VAS) and clinical symptoms, compared with the FP group. As a long-term trial, the clinical trials investigated the continuous application of TT-063 for 52 weeks, targeting 201 patients with osteoarthritis. The trials showed that 80% of the patients were able to continuously apply TT-063 over the trial period. Therefore, TT-063 was confirmed to possess good tolerability even during long-term use.
Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd. Announce Positive Results from Phase III Osteoporosis Trial
Apr 9 15
Chugai Pharmaceutical Co., Ltd. and Taisho Pharmaceutical Co., Ltd., have announced positive results from Japanese Phase III clinical trial of a bisphosphonate antiresorptive agent, ibandronate sodium hydrate oral agent, which is currently co-developed by Chugai and Taisho in Japan for the anticipated indication of osteoporosis. The MOVEST study, a randomized, multi center, double-blind, parallel group, controlled study, was conducted in approximately 400 patients (over 55 years of age) with osteoporosis to assess efficacy and safety of ibandronate oral formulation 100mg against ibandronate sodium hydrate injection [brand name: Bonviva IV Injection 1 mg Syringe (ibandronate injection)]. The increase in bone mineral density (BMD) of the lumbar spine (L2-L4) (percentage of relative change from baseline) at twelve month, the study's primary endpoint, was 5.22% for ibandronate oral formulation, and 5.34% [ 95% CI: 4.78% - 5.90% ] for ibandronate injection, respectively. The difference between the rate of change for ibandronate injection group of ibandronate oral formulation group (least squeares meane) was -0.23. It met the protocol criteria, a non-inferiority of ibandronate oral formulation to ibandronate injection has been demonstrated. The secondary endpoints of BMD gains in femur and inhibition on bone metabolic markers also showed similar effects between the two groups. No new safety signals were observed in the study. The safety profile was consistent with the previous overseas study results, and well tolerability of ibandronate oral formulation in osteoporotic patients was observed. Chugai filed a new drug application to the Ministry of Health, Labour and Welfare in February 2015, based on above and other data. Chugai and Taisho have been co-developing ibandronate oral formulation and Bonviva IV Injection in Japan as new treatment options for osteoporosis that improve adherence and offer patients wider choice of administration routes in Japan. Chugai and Taisho Toyama Pharmaceutical Co., Ltd. have been co-marketing Bonviva IV Injection, developed ahead of ibandronate oral formulation, since August, 2013 after Chugai obtained approval for osteoporosis indication in June, 2013. Following Bonviva IV Injection, Chugai and Taisho are determined to make efforts to obtain early approval of ibandronate oral formulation, a monthly oral agent and supply to patients and healthcare professionals.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|